Literature DB >> 8610986

Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report.

R B Nussenblatt1, S M Whitcup, M D de Smet, R R Caspi, A T Kozhich, H L Weiner, B Vistica, I Gery.   

Abstract

Intraocular inflammatory disease, or uveitis, is a disorder that mostly affects children and young adults. It is the cause of about 10% of the severe visual handicap in the United States. Many of the severe, sight-threatening uveitic conditions are thought to be driven by putative autoimmune mechanisms, often with high-dose oral prednisone use as treatment, along with cytotoxic agents, antimetabolites, and cyclosporine adjunctively. The feeding of the uveitogenic retinal S-Ag to rats immunized with the same antigen resulted in clinical protection. A pilot study in which two patients, one with pars planitis and the other with Behcet's disease, were fed with the retinal S-Ag resulted in these patients' immunosuppressive medication being decreased and/or stopped. The trial also provided us with information concerning dosage and expected immune responses. A randomized, masked study looking at the effect of feeding retinal antigens to uveitis patients is ongoing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610986     DOI: 10.1111/j.1749-6632.1996.tb21140.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.

Authors:  Eran Israeli; Yaron Ilan
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

2.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

Review 3.  Oral tolerance in disease.

Authors:  P Garside; A M Mowat; A Khoruts
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 4.  Oral tolerance.

Authors:  W Strober; B Kelsall; T Marth
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

5.  Type II collagen serology: a guide to clinical responsiveness to oral tolerance?

Authors:  U Gimsa; J Sieper; J Braun; N A Mitchison
Journal:  Rheumatol Int       Date:  1997       Impact factor: 2.631

Review 6.  Pharmacotherapy for Behcet's syndrome.

Authors:  A Saenz; M Ausejo; B Shea; G Wells; V Welch; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2000

7.  Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia.

Authors:  K J Becker; R M McCarron; C Ruetzler; O Laban; E Sternberg; K C Flanders; J M Hallenbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

Review 8.  Experimental autoimmune uveitis: molecular mimicry and oral tolerance.

Authors:  V K Singh; K Nagaraju
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

9.  Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.

Authors:  Eran Israeli; Ehud Zigmond; Gadi Lalazar; Athalia Klein; Nilla Hemed; Eran Goldin; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

Review 10.  Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus?

Authors:  Henry Yim Wu
Journal:  Clin Immunol       Date:  2008-10-19       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.